Stock HIK HIKMA PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 09:05:12 26/04/2024 pm IST 		5-day change 1st Jan Change
1,913 GBX +3.18% Intraday chart for Hikma Pharmaceuticals PLC +6.34% +6.93%
26/04 HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets Alphavalue
25/04 Hikma Pharmaceuticals backs outlook after making strong start to 2024 AN

Business Summary

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:

- generic injectable products (45.3%);

- brand name drugs (27.5%);

- generic products taken orally (26.7%);

- other (0.5%).

Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).

Number of employees: 9,100

Sales per Business

GBP in Million2022Weight2023Weight Delta
Injectables
41.8 %
926 45.3 % 968 41.8 % +4.48%
Generics
32.6 %
546 26.7 % 754 32.6 % +38.17%
Branded
24.8 %
561 27.5 % 574 24.8 % +2.39%
Others
0.7 %
11 0.5 % 17 0.7 % +60.07%

Sales per region

GBP in Million2022Weight2023Weight Delta
United States
60.0 %
1,163 56.9 % 1,389 60.0 % +19.35%
Middle East and North Africa
12.7 %
308 15.1 % 294 12.7 % -4.31%
Saudi Arabia
9.1 %
195 9.5 % 210 9.1 % +7.76%
Europe and Rest of the World
7.2 %
170 8.3 % 166 7.2 % -2.79%
Algeria
6.6 %
107 5.2 % 152 6.6 % +41.88%
Egypt
3.2 %
93 4.6 % 75 3.2 % -19.86%
North America
0.8 %
-- 19 0.8 % -
United Kingdom
0.4 %
6 0.3 % 9 0.4 % +36.25%

Managers

Managers TitleAgeSince
Riad Mishlawi CEO
 Chief Executive Officer 60 01/90/01
Khalid Nabilsi DFI
 Director of Finance/CFO 52 01/01/01
Said Darwazah CHM
 Chairman 66 01/81/01
Mazen Darwazah BRD
 Director/Board Member 65 01/85/01
Susan Ringdal IRC
 Investor Relations Contact - 01/05/01
Kristy Ronco SAM
 Sales & Marketing - 17/18/17
William Larkins PRN
 Corporate Officer/Principal - 01/22/01
Hussein Arkhagha HRO
 Human Resources Officer - 01/01/01
Majda Labadi PRN
 Corporate Officer/Principal - 01/85/01
Bassam Kanaan PRN
 Corporate Officer/Principal 58 01/01/01

Members of the board

Members of the board TitleAgeSince
Douglas Hurt BRD
 Director/Board Member 66 01/20/01
Nina Henderson BRD
 Director/Board Member 72 01/16/01
Victoria Hull BRD
 Director/Board Member 62 01/22/01
Mohammed Al-Husry BRD
 Director/Board Member 67 01/81/01
Mazen Darwazah BRD
 Director/Board Member 65 01/85/01
John Castellani BRD
 Director/Board Member 73 01/16/01
Said Darwazah CHM
 Chairman 66 01/81/01
Cynthia Flowers BRD
 Director/Board Member 64 01/19/01
Riad Mishlawi CEO
 Chief Executive Officer 60 01/90/01
Deneen Vojta BRD
 Director/Board Member 59 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 234,718,492 153,686,658 ( 65.48 %) 12,833,233 ( 5.467 %) 65.48 %

Shareholders

NameEquities%Valuation
Darhold Ltd.
27.04 %
60,000,000 27.04 % 1 454 M p
Wellington Management Co. LLP
5.208 %
11,556,882 5.208 % 280 M p
Capital Research & Management Co. (World Investors)
3.370 %
7,477,908 3.370 % 181 M p
BlackRock Advisors (UK) Ltd.
2.770 %
6,146,057 2.770 % 149 M p
The Vanguard Group, Inc.
1.844 %
4,091,653 1.844 % 99 M p
Norges Bank Investment Management
1.602 %
3,555,000 1.602 % 86 M p
Invesco Asset Management Ltd.
1.052 %
2,335,000 1.052 % 57 M p
FIL Investment Advisors (UK) Ltd.
1.001 %
2,221,000 1.001 % 54 M p
Capital Research & Management Co. (Global Investors)
0.9570 %
2,123,415 0.9570 % 51 M p
Royal London Asset Management Ltd.
0.8851 %
1,964,000 0.8851 % 48 M p

Company contact information

Hikma Pharmaceuticals Plc

1 New Burlington Place

W1S 2HR, London

+44 20 7399 2760

http://www.hikma.com
address Hikma Pharmaceuticals PLC(HIK)

Group companies

NameCategory and Sector
Hikma Ventures Ltd.
Logo Hikma Ventures Ltd.

Hikma Ventures Ltd.

Investment ManagersFinance

Hikma Ventures Ltd is a venture capital firm founded in 2015. The firm is headquartered in London, UK.

Investment Managers
Hikma Finance USA LLC
Finance/Rental/Leasing

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Hikma Pharmaceuticals PLC

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
23.83 USD
Average target price
28.64 USD
Spread / Average Target
+20.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HIKMA PHARMACEUTICALS PLC Stock Hikma Pharmaceuticals PLC
+6.93% 5.29B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HIK Stock
  4. Company Hikma Pharmaceuticals PLC